Articles by Lisa Harding, MD
An expert expresses concerns over NRx-100's "expanded access" for ketamine, questioning its safety claims and prioritizing market strategy over patient care.
Here's how embracing a comprehensive, patient-centered approach and staying informed about emerging treatments can help mental health professionals make a difference in the lives of patients with TRD.
Don't miss this session at the APA 2023 Annual Meeting in San Francisco!
Integrated Care and Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Electroconvulsive Therapy for Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Traditional Classes of Antidepressant Therapies
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Frontline Psychotherapy for Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Treatment-Resistant Depression: Financial Support for Esketamine Therapy
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Incorporating Esketamine into Practice for Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Getting Certified to Administer Esketamine for Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Treatment-Resistant Depression: Administering Esketamine to Patients
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM REMS Safety Program for Esketamine in Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Response to Esketamine Therapy for Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Monitoring Patients on Esketamine Therapy for Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Esketamine for Treatment-Resistant Depression: Patient Selection Criteria
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Intranasal Esketamine for Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Current Guidelines for Managing Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM IV Ketamine for Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM Prevalence of Treatment-Resistant Depression
BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM
Prevalence of Treatment-Resistant Depression
Various Definitions of Treatment Resistant Depression